Hanmi Pharmaceuticals Co Ltd (128940)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Hanmi Pharmaceuticals Co Ltd (128940)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH297367D
  • |
  • Pages: 42
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Hanmi Pharmaceuticals Co Ltd (Hanmi Pharma) a subsidiary of Hanmi Science Co Ltd is a pharmaceutical company that develops prescription drugs. The company manufactures and supplies prescription drugs and over the counter drugs. Its prescription drugs include osteoporosis, antibiotics, antidiarrheal, liver supplements and antiemetics. Hanmi Pharma provides OTC products such as vitamins, nutritional supplements and calcium supplement, among others. The company's products are used in the treatment of cancer, depression, dementia, dermatology, diabetes, anti-inflammatory, cardiovascular, epilepsy, hepatitis, hypnotics, osteoarthritis, gastrointestinal, osteoporosis and others. It operates through its manufacturing facilities located in different parts of South Korea. Hanmi Pharma is headquartered in Seoul, South Korea.

Hanmi Pharmaceuticals Co Ltd (128940)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Hanmi Pharmaceuticals Co Ltd, Medical Devices Deals, 2011 to YTD 2017 10

Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deal Details 14

Partnerships 14

Cell>Point And Hyun IMC Expand Licensing Agreement To Include Hanmi Pharma For Cancer And Heart Disease Imaging 14

Serenus Biotherapeutics Enters into Co-Marketing with Hanmi Pharma 15

Hanmi Pharma Enters into Co-Marketing Agreement with Novartis Korea 16

Hanmi Pharma Enters into Co-promotion Agreement with Merck Sharp & Dohme Korea 16

Kainos Medicine Enters into Co-Development Agreement with Hanmi Pharm 17

Hanmi Pharma Enters Into Co-Marketing Agreement With Sanofi-Aventis For Ibestin 18

Hanmi Pharma Enters Into Co-Development Agreement With GlaxoSmithKline For EBF Products 19

Licensing Agreements 19

Genentech to Enter into Licensing Agreement with Hanmi Pharma 19

Sanofi to Enter into Licensing Agreement with Hanmi Pharma 20

ZAI Lab Enters into Licensing Agreement with Hanmi Pharma 22

Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 22

Eli Lilly to Enter into Licensing Agreement with Hanmi Pharma 23

Hanmi Pharma Expands Licensing Agreement with Kinex Pharma for Orascovery Program 24

Spectrum Pharma Enters into Licensing Agreement with Hanmi Pharma for Poziotinib 25

Allegro Ophthalmics Enters into Licensing Agreement with Hanmi Pharma for Luminate 26

Hanmi Pharm Enters into Licensing Agreement with Luye Pharma for Poziotinib 27

Access Pharma Enters Into Licensing Agreement With Hanmi Pharma For MuGard 28

Hanmi Pharma Expands Licensing Agreement With Kinex Pharma For Orascovery Program 29

Kinex Pharma Expands Licensing Agreement With Hanmi Pharma 30

Amneal Pharma Enters Into Licensing Agreement With Hanmi Pharma For Nexium Alternative 31

Hanmi Pharma Enters Into Licensing Agreement With AngioLab For Anti-Obesity Botanical Drug 32

Spectrum Pharma Enters Into Licensing Agreement With Hanmi Pharma For SPI-2012 33

Kinex Pharma Enters Into Licensing Agreement With Hanmi Pharma 34

Hanmi Pharma Expands Licensing Agreement With Merck For Amosartan 36

Kinex Pharma Enters Into Licensing Agreement With Hanmi Pharma For KX01 37

Acquisition 38

Hanmi Pharma to Invest USD20 Million in Allegro Ophthalmics 38

Hanmi Pharmaceuticals Co Ltd-Key Competitors 39

Key Employees 40

Locations And Subsidiaries 41

Head Office 41

Other Locations & Subsidiaries 41

Appendix 42

Methodology 42

About GlobalData 42

Contact Us 42

Disclaimer 42

List of Figures

Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Hanmi Pharmaceuticals Co Ltd, Medical Devices Deals, 2011 to YTD 2017 10

List of Tables

Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2015 1

Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Hanmi Pharmaceuticals Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 9

Hanmi Pharmaceuticals Co Ltd, Medical Devices Deals, 2011 to YTD 2017 10

Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Cell>Point And Hyun IMC Expand Licensing Agreement To Include Hanmi Pharma For Cancer And Heart Disease Imaging 14

Serenus Biotherapeutics Enters into Co-Marketing with Hanmi Pharma 15

Hanmi Pharma Enters into Co-Marketing Agreement with Novartis Korea 16

Hanmi Pharma Enters into Co-promotion Agreement with Merck Sharp & Dohme Korea 16

Kainos Medicine Enters into Co-Development Agreement with Hanmi Pharm 17

Hanmi Pharma Enters Into Co-Marketing Agreement With Sanofi-Aventis For Ibestin 18

Hanmi Pharma Enters Into Co-Development Agreement With GlaxoSmithKline For EBF Products 19

Genentech to Enter into Licensing Agreement with Hanmi Pharma 19

Sanofi to Enter into Licensing Agreement with Hanmi Pharma 20

ZAI Lab Enters into Licensing Agreement with Hanmi Pharma 22

Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 22

Eli Lilly to Enter into Licensing Agreement with Hanmi Pharma 23

Hanmi Pharma Expands Licensing Agreement with Kinex Pharma for Orascovery Program 24

Spectrum Pharma Enters into Licensing Agreement with Hanmi Pharma for Poziotinib 25

Allegro Ophthalmics Enters into Licensing Agreement with Hanmi Pharma for Luminate 26

Hanmi Pharm Enters into Licensing Agreement with Luye Pharma for Poziotinib 27

Access Pharma Enters Into Licensing Agreement With Hanmi Pharma For MuGard 28

Hanmi Pharma Expands Licensing Agreement With Kinex Pharma For Orascovery Program 29

Kinex Pharma Expands Licensing Agreement With Hanmi Pharma 30

Amneal Pharma Enters Into Licensing Agreement With Hanmi Pharma For Nexium Alternative 31

Hanmi Pharma Enters Into Licensing Agreement With AngioLab For Anti-Obesity Botanical Drug 32

Spectrum Pharma Enters Into Licensing Agreement With Hanmi Pharma For SPI-2012 33

Kinex Pharma Enters Into Licensing Agreement With Hanmi Pharma 34

Hanmi Pharma Expands Licensing Agreement With Merck For Amosartan 36

Kinex Pharma Enters Into Licensing Agreement With Hanmi Pharma For KX01 37

Hanmi Pharma to Invest USD20 Million in Allegro Ophthalmics 38

Hanmi Pharmaceuticals Co Ltd, Key Competitors 39

Hanmi Pharmaceuticals Co Ltd, Key Employees 40

Hanmi Pharmaceuticals Co Ltd, Other Locations 41

Hanmi Pharmaceuticals Co Ltd, Subsidiaries 41

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Hanmi Pharmaceuticals Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16088
Site License
USD 500 INR 32175
Corporate User License
USD 750 INR 48263

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com